Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was completed on 6 October 2026. The consideration for the deal consists of both cash and shares. Both the buyer and the target are based in the United States and operate within the healthcare sector. The announcement date is recorded as 9 October 2026, although the completion date precedes this by three days. This deal represents a direct acquisition of the target entity by the buyer. No further details regarding specific strategic motivations or comparative market analysis are provided in the available data. The structure involves a combination of financial instruments to facilitate the transfer of ownership. The healthcare industry context suggests a focus on pharmaceutical or life sciences capabilities, though specific operational details remain unreported. The deal value is reported as a headline offer figure. All parties involved are US entities. The transaction has reached its final stage. The status of the deal is confirmed as completed. There are no pending regulatory hurdles mentioned in the record. The financial terms are fixed at the reported amount. The share component of the consideration implies an equity stake in the buyer for the target’s owners. The cash component provides immediate liquidity. The overall structure is standard for a strategic acquisition of this scale. The timeline indicates a swift process from completion to announcement. The data confidence levels are high for most fields, with medium confidence for the announcement date. The sector label is clearly defined as healthcare. The countries of operation are identical for both entities. The deal type is explicitly classified as a strategic acquisition. No other figures or names are included in this summary. The transaction is subject to regulatory approval.